Medivation Inc (NASDAQ:MDVN)
| 48.86 Data as of May 24 |  -0.95 / -1.91%Today’s Change | 39.62 Today|||52-Week Range 59.24 | -4.50% Year-to-Date |
Latest MDVN News | Press Releases
| Bayer's Xofigo Cleared in the US - Analyst Blog May 16 / Zacks.com | Medivation Loss Narrower Than Expected - Analyst Blog May 13 / Zacks.com |
Today’s Trading
| Previous close | 49.81 |
| Today’s open | 49.75 |
| Day’s range | 48.32 - 49.75 |
| Volume | 904,053 |
| Average volume (3 months) | 1,239,028 |
| Market cap | $3.7B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -0.90% |
| Earnings growth (this year) | -71.73% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | +200.88% |
| P/E ratio | NM |
| Price/Sales | 20.69 |
| Price/Book | 49.61 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SLXPSalix Pharmaceutical... | +0.70 | +1.17% |
| THRXTheravance Inc | -0.54 | -1.47% |
| JAZZJazz Pharmaceuticals... | +0.75 | +1.19% |
| ENDPEndo Health Solution... | -0.40 | -1.17% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $181.7M |
| Annual profit (last year) | -$41.3M |
| Net profit margin | -22.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director David T. Hung, MD |
Secretary, Chief Financial & Business Officer Clarence Patrick Machado |
Corporate headquarters San Francisco, California |
Forecasts
